Brief: Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer
30/05/2026 13:14
BRIEF-Veracyte Says Enzamet Trial Shows Decipher Prostate Test Identifies Chemotherapy Benefit In Metastatic Prostate Cancer May 30 (Reuters) - Veracyte Inc VCYT.O:
VERACYTE - ENZAMET TRIAL SHOWS DECIPHER PROSTATE TEST IDENTIFIES CHEMOTHERAPY BENEFIT IN METASTATIC PROSTATE CANCER
Source text: ID:nBw4lb7kHa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina